Ribostamycin

DB03615

small molecule approved experimental

Deskripsi

Ribostamycin is an aminoglycoside antibioticA187166 isolated from Streptomyces ribosidificusA187178 listed as one of the World Health Organization's critically important antimicrobials.L9071

Struktur Molekul 2D

Berat 454.4727
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

868 Data
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Ribostamycin.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Ribostamycin.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Ribostamycin.
Cisatracurium Ribostamycin may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Ribostamycin.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Ribostamycin.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Ribostamycin.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Ribostamycin.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Ribostamycin.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Ribostamycin.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Ribostamycin.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Ribostamycin.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Ribostamycin.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Ribostamycin.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Ribostamycin.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Ribostamycin.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Ribostamycin.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Ribostamycin.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Ribostamycin.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Ribostamycin.
Carboplatin The risk or severity of ototoxicity and nephrotoxicity can be increased when Ribostamycin is combined with Carboplatin.
Foscarnet The risk or severity of nephrotoxicity can be increased when Ribostamycin is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ribostamycin.
Tenofovir disoproxil Ribostamycin may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Ribostamycin may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Ribostamycin may increase the nephrotoxic activities of Tenofovir.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ribostamycin.
Zoledronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Zoledronic acid.
Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Alendronic acid.
Ibandronate The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Ibandronate.
Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Clodronic acid.
Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Risedronic acid.
Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Etidronic acid.
Incadronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Incadronic acid.
Taxifolin The risk or severity of nephrotoxicity can be increased when Taxifolin is combined with Ribostamycin.
Licofelone The risk or severity of nephrotoxicity can be increased when Licofelone is combined with Ribostamycin.
Polmacoxib The risk or severity of nephrotoxicity can be increased when Polmacoxib is combined with Ribostamycin.
Ebselen The risk or severity of nephrotoxicity can be increased when Ebselen is combined with Ribostamycin.
Flurbiprofen axetil The risk or severity of nephrotoxicity can be increased when Flurbiprofen axetil is combined with Ribostamycin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Ribostamycin is combined with Acetyldigitoxin.
Deslanoside The risk or severity of adverse effects can be increased when Ribostamycin is combined with Deslanoside.
Ouabain The risk or severity of adverse effects can be increased when Ribostamycin is combined with Ouabain.
Digitoxin The risk or severity of adverse effects can be increased when Ribostamycin is combined with Digitoxin.
Oleandrin The risk or severity of adverse effects can be increased when Ribostamycin is combined with Oleandrin.
Cymarin The risk or severity of adverse effects can be increased when Ribostamycin is combined with Cymarin.
Proscillaridin The risk or severity of adverse effects can be increased when Ribostamycin is combined with Proscillaridin.
Metildigoxin The risk or severity of adverse effects can be increased when Ribostamycin is combined with Metildigoxin.
Lanatoside C The risk or severity of adverse effects can be increased when Ribostamycin is combined with Lanatoside C.
Gitoformate The risk or severity of adverse effects can be increased when Ribostamycin is combined with Gitoformate.
Acetyldigoxin The risk or severity of adverse effects can be increased when Ribostamycin is combined with Acetyldigoxin.
Peruvoside The risk or severity of adverse effects can be increased when Ribostamycin is combined with Peruvoside.
Torasemide The serum concentration of Ribostamycin can be increased when it is combined with Torasemide.
Bumetanide The serum concentration of Ribostamycin can be increased when it is combined with Bumetanide.
Etacrynic acid The serum concentration of Ribostamycin can be increased when it is combined with Etacrynic acid.
Piretanide The serum concentration of Ribostamycin can be increased when it is combined with Piretanide.
Azosemide The serum concentration of Ribostamycin can be increased when it is combined with Azosemide.
Tripamide The serum concentration of Ribostamycin can be increased when it is combined with Tripamide.
Flucloxacillin The serum concentration of Ribostamycin can be decreased when it is combined with Flucloxacillin.
Phenoxymethylpenicillin The serum concentration of Ribostamycin can be decreased when it is combined with Phenoxymethylpenicillin.
Dicloxacillin The serum concentration of Ribostamycin can be decreased when it is combined with Dicloxacillin.
Carbenicillin The serum concentration of Ribostamycin can be decreased when it is combined with Carbenicillin.
Nafcillin The serum concentration of Ribostamycin can be decreased when it is combined with Nafcillin.
Hetacillin The serum concentration of Ribostamycin can be decreased when it is combined with Hetacillin.
Benzylpenicilloyl polylysine The serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicilloyl polylysine.
Mezlocillin The serum concentration of Ribostamycin can be decreased when it is combined with Mezlocillin.
Cyclacillin The serum concentration of Ribostamycin can be decreased when it is combined with Cyclacillin.
Benzylpenicillin The serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicillin.
Azlocillin The serum concentration of Ribostamycin can be decreased when it is combined with Azlocillin.
Cloxacillin The serum concentration of Ribostamycin can be decreased when it is combined with Cloxacillin.
Amdinocillin The serum concentration of Ribostamycin can be decreased when it is combined with Amdinocillin.
Bacampicillin The serum concentration of Ribostamycin can be decreased when it is combined with Bacampicillin.
Meticillin The serum concentration of Ribostamycin can be decreased when it is combined with Meticillin.
Pivampicillin The serum concentration of Ribostamycin can be decreased when it is combined with Pivampicillin.
Pivmecillinam The serum concentration of Ribostamycin can be decreased when it is combined with Pivmecillinam.
Ticarcillin The serum concentration of Ribostamycin can be decreased when it is combined with Ticarcillin.
Azidocillin The serum concentration of Ribostamycin can be decreased when it is combined with Azidocillin.
Carindacillin The serum concentration of Ribostamycin can be decreased when it is combined with Carindacillin.
Sultamicillin The serum concentration of Ribostamycin can be decreased when it is combined with Sultamicillin.
Temocillin The serum concentration of Ribostamycin can be decreased when it is combined with Temocillin.
Epicillin The serum concentration of Ribostamycin can be decreased when it is combined with Epicillin.
Pheneticillin The serum concentration of Ribostamycin can be decreased when it is combined with Pheneticillin.
Carfecillin The serum concentration of Ribostamycin can be decreased when it is combined with Carfecillin.
Propicillin The serum concentration of Ribostamycin can be decreased when it is combined with Propicillin.
Clometocillin The serum concentration of Ribostamycin can be decreased when it is combined with Clometocillin.
Sulbenicillin The serum concentration of Ribostamycin can be decreased when it is combined with Sulbenicillin.
Penamecillin The serum concentration of Ribostamycin can be decreased when it is combined with Penamecillin.
Talampicillin The serum concentration of Ribostamycin can be decreased when it is combined with Talampicillin.
Aspoxicillin The serum concentration of Ribostamycin can be decreased when it is combined with Aspoxicillin.
Metampicillin The serum concentration of Ribostamycin can be decreased when it is combined with Metampicillin.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ribostamycin.
Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ribostamycin.
Lymecycline The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Ribostamycin.
Clomocycline The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Ribostamycin.
Quinine The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Ribostamycin.
Tigecycline The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Ribostamycin.
Oxytetracycline The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Ribostamycin.
Demeclocycline The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Ribostamycin.
Magnesium sulfate The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Ribostamycin.
Metacycline The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Ribostamycin.
Minocycline The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Ribostamycin.

Target Protein

30S ribosomal protein S12 rpsL
Protein disulfide-isomerase P4HB
Aminoglycoside N(6')-acetyltransferase type 1
Aminoglycoside 2'-N-acetyltransferase aac

Referensi & Sumber

Synthesis reference: Eiichi Akita, Tsutomu Tsuchiya, Shinichi Kondo, Shuntaro Yasuda, Sumio Umezawa, Hamao Umezawa, "1-N-((S)-.alpha.-substituted-.omega.-aminoacyl)-neamine or -ribostamycin and the production thereof." U.S. Patent US4008218, issued February, 1974.
Artikel (PubMed)
  • PMID: 924894
    Baud H, Betencourt A, Peyre M, Penasse L: Ribostamycin, as an intermediate in the biosynthesis of neomycin. J Antibiot (Tokyo). 1977 Sep;30(9):720-3. doi: 10.7164/antibiotics.30.720.
  • PMID: 28685903
    Zachman-Brockmeyer TR, Thoden JB, Holden HM: The structure of RbmB from Streptomyces ribosidificus, an aminotransferase involved in the biosynthesis of ribostamycin. Protein Sci. 2017 Sep;26(9):1886-1892. doi: 10.1002/pro.3221. Epub 2017 Jul 23.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul